Mixed Phenotype Acute Leukemia — Trials

Mixed Phenotype Acute Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

96 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 29
Ph III recruiting: 2
Growth YoY: —
Industry share: 17%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: 41.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05326516	A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia	completed	Phase 1	30	Syndax PharmaceuticalsINDUSTRY	2	Aug 13, 2024	clinicaltrials
NCT02728050	Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	completed	Phase 1 / Phase 2	84	University of WashingtonOTHER	1	Jul 5, 2023